Q-omics provides the consensus-scored CCDC186 profile across patient tissues and cancer cell-line models. CCDC186 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CCDC186 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, CCDC186 RNA expression shows 21,116 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where CCDC186 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC186 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC186 survival associations across molecular data types. CCDC186 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC186 RNA expression–survival associations across cancer types. High CCDC186 expression shows unfavorable associations in ACC and BLCA, but favorable associations in KIRC, HNSC, SKCM and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CCDC186 RNA expression.
This table summarizes CCDC186 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CCDC186. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC186 shows lower tumor expression in KIRC, THCA, KIRP, KICH, COAD and LUSC. The KIRC box plot shows higher CCDC186 RNA expression in normal versus tumor tissue (log2 FC = −1.024, t-test p < 0.001).
This table shows molecular features associated with CCDC186 in patient tissues and cancer cell lines. In patient samples, CCDC186 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC186 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
